ResMed Inc. (CHESS) Company Profile (ASX:RMD)

Analyst Ratings

Consensus Ratings for ResMed Inc. (CHESS) (ASX:RMD) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for ResMed Inc. (CHESS) (ASX:RMD)
Show:
DateFirmActionRatingPrice TargetActions
3/16/2015Deutsche Bank AGReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/21/2014JPMorgan Chase & Co.Reiterated RatingOverweight$5.91View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for ResMed Inc. (CHESS) (ASX:RMD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for ResMed Inc. (CHESS) (ASX:RMD)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ResMed Inc. (CHESS) (ASX:RMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ResMed Inc. (CHESS) (ASX:RMD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for ResMed Inc. (CHESS) (ASX:RMD)
DateHeadline
07/20/16 09:00 AMThe easy way to start building a $1 million share portfolio in FY 2017
05/31/16 07:48 AMIs Nanosonics Ltd a blue-chip share of tomorrow? - It also has a management team that can draw from the success of blue-chip medical devices businesses on the ASX like Cochlear Limited (ASX: COH) and ResMed Inc. (CHESS) (ASX: RMD). Notably, Nanosonics' CEO is a former employee of Cochlear's Global ...
04/26/16 07:45 PMResMed books mixed third-quarter results - [Other] - ResMed's third-quarter results have come in mixed as the medical equipment maker spends more on research and new products. Chief executive Mick Farrell on Wednesday said the group was "unlocking value" by expanding into new products and tech-driven mobile medical devices. "We are liberating healthcare data and unlocking value by providing actionable connected care solutions for patients, physicians, providers, and payers," Mr Farrell said in a statement.
04/26/16 06:42 PMResMed Q3 revenue up 7 pct - [Other] - Medical device maker Resmed has lifted third quarter revenue seven per cent to $US453.9 million ($A586.13 million), or excluding exchange rate fluctuations, nine per cent in constant currency terms. However, ...
04/26/16 04:29 PMResMed misses 3Q profit forecasts - [AP] - On a per-share basis, the San Diego-based company said it had net income of 63 cents. Earnings, adjusted for costs related to mergers and acquisitions and amortization costs, were 68 cents per share. The ...
04/26/16 03:14 PMResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2016 - [Other] - SAN DIEGO, April 26, 2016 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced results for its quarter ended March 31, 2016. Revenue for the quarter was $453.9 million, a 7 percent increase compared ...
04/15/16 04:07 PMResMed Files Patent Infringement Action Against BMC and 3B CPAP Devices - [Other] - The U.S. Patent and Trademark Office has already ruled that patent claims from a ResMed patent asserted against BMC and 3B in a new ITC case are valid SAN DIEGO, April 14, 2016 - ResMed, the world's leading ...
04/08/16 01:50 PMResMed: Strong Cash Balance, Product Portfolio Drive Growth - [Zacks] - ResMed (RMD) currently has a strong cash balance, as evident from $269.5 million in cash flow from operations generated during the fiscal 2016 second quarter
04/07/16 08:17 AMResMed (RMD) Stock Gets 'Underweight' Rating at Barclays - [at TheStreet] - ResMed (RMD) stock coverage was reinstated with an 'underweight' rating and $55 price target at Barclays on Thursday morning.
02/04/16 01:36 PMResMed (RMD) Announces Completion of Inova Labs Acquisition - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. ResMed (NYSE: RMD) announced it completed the acquisition of Inova Labs Inc., a privately-held medical device company that develops and commercializes innovative oxygen ...
02/03/16 06:19 PMWhy AGL Energy Ltd & Fisher & Paykel Healthcare Corp Ltd could offer growth & income - [at Motley Fool] - AGL Energy Ltd (ASX:AGL) and Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) can boost your portfolio.
01/25/16 12:15 PMResMed Inc. (RMD) Jumped To A 6-Week High On Strong Q2 Earnings - ResMed Inc. (RMD) reported second quarter EPS of $0.69 after the bell Thursday, compared to $0.65 in the previous year. The consensus estimate was for EPS of $0.66. ResMed gapped open sharply higher Friday and climbed in early trade. Profit taking set in ...
01/22/16 11:17 AMWhy ResMed Inc's Stock Is Up Big Today -
01/21/16 04:50 PMResmed lifts 2Q revenue 7% to $US454.5m - [Other] - Medical device maker Resmed has lifted second quarter revenue seven per cent to $US454.5 million ($A651 million). The increase would have been even higher, at 13 per cent, but for the increased strength of the US dollar, in which Resmed reports its financial results. "ResMed has transformed into a tech-driven medical device company," chief executive Mick Farrell said.
01/21/16 03:46 PMResMed tops Street 2Q forecasts - [AP] - The San Diego-based company said it had net income of 64 cents per share. Earnings, adjusted for one-time gains and costs, were 69 cents per share. The results beat Wall Street expectations. The average ...
01/19/16 03:19 PMResMed (RMD) Stock Downgraded at Barclays -

Social

About ResMed Inc. (CHESS)

ResMed Inc. (CHESS) logoResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: ASX
  • Symbol: RMD
  • CUSIP:
Key Metrics:
  • Previous Close: $6.70
  • 50 Day Moving Average: $8.33
  • 200 Day Moving Average: $7.93
  • P/E Ratio: 36.23
  • P/E Growth: 2.59
  • Market Cap: $12.41B
  • Current Year EPS Consensus Estimate: $ EPS
  • Next Year EPS Consensus Estimate: $ EPS
Additional Links: